AD-A088 257   LETTERMAN ARMY INST OF RESEARCH SAN FRANCISCO CA   F/G 6/1
                PURIFICATION OF TRANSKETOLASE FROM HUMAN ERYTHROCYTES. 1. USING--ETC(U)
   JUL 80   M H DONG, E L MCGOWN, P P WARING
UNCLASSIFIED   LAIR-TN-13   NL

END
DATE
FILMED
9-80
DTIC

1.0

1.1

1.25

2.8   2.5

3.2   2.2

3.6

4.0   2.0

1.8

1.4   1.6

MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS 1963 A

LEVEL II

(12)

TECHNICAL NOTE NO. 13

(13) ISC

(6) PURIFICATION OF TRANSKETOLASE FROM HUMAN ERYTHROCYTES,

I. Using Solvent Denaturation as the Initial Step.

AD A088257

(10)

MICHAEL H. DONG, MPH, MPA, CPT MS
EVELYN L. McGOWN, PhD
PAUL P. WARING, BS
JAMES H. SKALA, PhD

HOWERDE E. SAUBERLICH, PhD

(11) Jul

(9) Technical note. 3-7 71-Feb 28,

DIVISION OF RESEARCH SUPPORT
and
DIVISION OF NUTRITION TECHNOLOGY

(14) LAIR-TN-13

(16) 3M162772A 811

DTIC
S ELECTE D
AUG 26 1980
E

JULY 1980

LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO CALIFORNIA 94129

80 8 14 032

20 July 80

(Date)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER LAIR Technical Note #13 ✓	**2. GOVT ACCESSION NO.** AD-A088 957	**3. RECIPIENT'S CATALOG NUMBER**
4. TITLE (and Subtitle) Purification of Transketolase from Human Erythrocutes I. Using solvent denaturation as the initial step		**5. TYPE OF REPORT & PERIOD COVERED** Interim October 1979–February 1980
		6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s) Michael H. Dong, MPH, MPA, CPT, MSC; Evelyn McGown Ph.D., Paul P. Waring, BS, James H. Skala, Ph.D.; Howerde E. Sauberlich, Ph.D.		**8. CONTRACT OR GRANT NUMBER(s)**
9. PERFORMING ORGANIZATION NAME AND ADDRESS Division of Research Support and Division of Nutrition Technology, Letterman Army Institute of Research, Presidio of San Francisco, CA 94129		**10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS** 62772A 3M162772811 002
11. CONTROLLING OFFICE NAME AND ADDRESS U.S. Army Medical Research & Development Command Fort Detrick, Frederick, MD 21701		**12. REPORT DATE** July 1980
		13. NUMBER OF PAGES 13
14. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office)		**15. SECURITY CLASS. (of this report)** UNCLASSIFIED
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE

16. DISTRIBUTION STATEMENT (of this Report)

APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED

17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)

18. SUPPLEMENTARY NOTES

19. KEY WORDS (Continue on reverse side if necessary and identify by block number)
Vitamin B_1 analysis, enzyme purification, red cell transketolase

20. ABSTRACT (Continue on reverse side if necessary and identify by block number)
An attempt was made to purify human erythrocyte transketolase (EC 2.2.1.1) by the use of solvent denaturation as the initial isolation step. This involved the use of 95% ethanol solution (-20 C) to denature a large amount of the hemoglobin and other non-transketolase proteins. Although the data obtained from this study did not contribute to sound statistical values because of the small sample size, they tended to support the application of the method as an effective initial step in the purification of human erythrocyte transketolase. The mean recovery of the enzyme for five trials conducted with blood obtained from⟶

DD FORM 1473 EDITION OF 1 NOV 65 IS OBSOLETE

20. (cont) three donors was 61 ± 3%. The purification ranged from 21 to 23. The method permitted the removal of nearly 95% of the hemoglobin initially present.

PURIFICATION OF TRANSKETOLASE FROM HUMAN ERYTHROCYTES

I. Using Solvent Denaturation as the Initial Step

ABSTRACT

An attempt was made to purify human erythro-
cyte transketolase (EC 2.2.1.1) by the use of solvent
denaturation as the initial isolation step. This
involved the use of 95% ethanol solution (-20 C) to
denature a large amount of the hemoglobin and other
non-transketolase proteins. Although the data ob-
tained from this study did not contribute to sound
statistical values because of small sample sizes,
they tended to support the application of the method
as an effective initial step in the purification of
human erythrocyte transketolase. The mean recovery
of the enzyme for five trials conducted with blood
obtained from three donors was 61 ± 3%. The puri-
fication ranged from 21 to 23. The method permitted
the removal of nearly 95% of the hemoglobin initially
present.

INTRODUCTION

In 1967, Sauberlich (1) reviewed extensively the various assay
methods used for assessment of thiamin adequacy in man. He concluded
that the best of these methods was the measurement of erythrocyte trans-
ketolase (TK) activity. Since 1950, it has been known that the enzyme
transketolase requires thiamin pyrophosphate (TPP) as a co-factor in
the metabolism of pentose (2,3). The use of red cell TK in the func-
tional evaluation of thiamin nutritional status in man was not proposed
until after 1960.

In the last two decades, several methods have been described for
the determination of TK activity in man: measurement of (a) formation of
sedoheptulose-7-phosphate (S-7-P) (7,8), (b) formation of glycer-
aldehyde-3-phosphate (GAP) (9-13), (c) formation of hexose phosphates

(4,14,15), and (d) decrease of pentose phosphates (14,15). Since TK
values obtained from these attempts have little diagnostic usefulness
for patients with severe liver or other related disease, there has
been a considerable controversy in recent years as to whether or not
the activity of TK, as presently measured, truly reflects thiamin nu-
tritional status in man (1, 16-18). Figure 1 shows the pentose phosphate
pathway.

$$R\text{-}5\text{-}P \xrightarrow{\text{R-5-P Isomerase}} Ru\text{-}5\text{-}P$$

$$Ru\text{-}5\text{-}P \xrightarrow{\text{Ru-5-P Epimerase}} Xu\text{-}5\text{-}P$$

$$Xu\text{-}5\text{-}P + R\text{-}5\text{-}P \xrightarrow{\text{TK}} S\text{-}7\text{-}P + GAP$$

$$S\text{-}7\text{-}P - GAP \xrightarrow{\text{TA}} E\text{-}4\text{-}P + F\text{-}6\text{-}P$$

$$Xu\text{-}5\text{-}P - E\text{-}4\text{-}P \xrightarrow{\text{TK}} F\text{-}6\text{-}P + GAP$$

$$F\text{-}6\text{-}P \xrightarrow{\text{PGI}} G\text{-}6\text{-}P$$

Figure 1. Pentose phosphate pathway.*†

Abbreviations: R-5-P = ribose-5-phosphate, Ru-5-P = ribulose-5-phosphate,
Xu-5-P = xylulose-5-phosphate, S-7-P = sedoheptulose-7-phosphate,
GAP = glyceraldehyde-3-phosphate,
E-4-P = erythrose-4-phosphate,
PGI = phosphoglucoisomerase,
G-6-P = glucose-6-phosphate,
TK = transketolase,   TA = transaldolase.

†Reproduced from figure presented in reference 19 of this manuscript.

In all the methods used heretofore to determine the activity of TK
in erythrocytes, only ribose-5-phosphate (R-5-P) has been added to the
assay system as a substrate. Since external substrate xylulose-5-
phosphate (Xu-5-P) was not known or available when most of these enzyme
assays were developed, this TK substrate normally was not used for
carrying out the enzyme assay. It was instead assumed to be provided

2

internally from R-5-P (first two reactions outlined in Figure 1).
According to Brin (19), the enzymes catalyzing for the first two re-
actions outlined above are not rate-limiting. There is, however, some
evidence that this may not be a valid assumption (Waring, unpublished
data).

In any event, to validate the measurement of TK activity in human
erythrocytes, one must first demonstrate that in the hemolysate system
TK is the rate-limiting enzyme. A second requirement is that R-5-P does,
in fact, equilibrate with the ketopentoses. These, in turn, necessitate
the isolation or purification of TK from human red cells. After purified
TK from human red cells becomes available, one then can test the hypo-
thesis that the activities of both the ribulose-5-phosphate (Ru-5-P)
epimerase and R-5-P isomerase are much higher than the activity of TK.
For example, various amounts of purified TK can then be added to induce
the TK-related reactions in a known quantity of hemolysate to observe
the enzymatic effect on the formation of GAP or S-7-P. If the activities
of other related enzymes are, in fact, excessively higher, the induced
reaction rate probably will not be limited, regardless of the amount of
purified enzyme added. The purification of TK from human red cells can
lead to an understanding of the true kinetic properties of the enzyme
as well.

Transketolase has been isolated and purified from many sources
(20-24), but in only one instance from human erythrocytes (25), to our
knowledge. These investigators (25) used hydroxylapatite adsorption as
the initial isolation step.

The process of using the hydroxylapatite adsorption method (25)
as the possible initial isolation step is both laborious and time-
consuming. Furthermore, we tried to use this method several times but
had little success. This technical note describes the use of solvent
denaturation as an initial step in the isolation or purification of TK
from human erythrocytes. This method has been effective, is relatively
simple to perform, and requires only about two hours to accomplish.

MATERIALS AND METHODS

Chemicals. Glycerin-3-phosphate-dehydrogenase/triosephosphate-
isomerase (GPH/TIM) obtained from rabbit muscle was purchased from
Boehringer Mannheim Biochemicals (Indianapolis, Indiana). Other
chemicals including yeast R-5-P were products of Sigma Company (St Louis,
Missouri).

Source of enzyme. Erythrocytes were prepared from outdated (4- to
5-week old) heparinized human blood. We separated the cells from plasma
and washed them three times with 0.9% NaCl by centrifugation at 900 x G
for 10 minutes. We then lysed the erythrocytes by adding one volume of
0.02 M K_2HPO_4 at pH 7.8 and two volumes of distilled water. After
allowing the hemolysate to stand for several hours, we removed the
stroma by centrifugation at 2,000 x G for 10 minutes and collected the

supernatant fraction for enzyme isolation. All steps subsequent to the separation of erythrocytes were carried out at 4 C, except where otherwise noted.

Solvent denaturation. Our method is based on the one described by Oh, et al (26) who used the procedure to purify red cell glutathione peroxidase. To every 100 ml of hemolysate, we stirred in 82 ml of 95% ethanol (-20 C); and then we added slowly 35 ml of carbon tetrachloride (25 C) over a 90-second interval. (Ethanol can be cooled to -30 C or lower by simply placing the flask containing the solvent in a dry ice/acetone bath.) After most of the precipitate had formed, we added 300 ml of distilled water (per 100 ml hemolysate) and removed the bulk of the precipitate by filtering through cheese cloth. Centrifugation at 2,000 x G for 15 minutes removed the remaining precipitate and excessive carbon tetrachloride.

Transketolase assay. The reaction mixture contained the following components: 2.90 ml assay solution; 0.04 ml of hemolysate; and 0.76 ml of mixture containing enzyme extract and/or TRIS buffer in preselected proportions to obtain a standard curve (Figure 2). The 2.90 ml assay solution was composed of 2.80 ml NADH/GPH/TIM solution and either 0.10 ml R-5-P or, in the case of a blank, 0.10 ml TRIS buffer. The reaction was monitored at 37 C by the decrease in absorbance at 340 nm. At 340 nm the optical density will change in proportion to the amount of NADH oxidized to NAD^+. This oxidation of NADH is attributed to the activity and availability of GAP accumulated in the assay system. (The GAP is synthesized through a series of pentose-phosphate-related reactions and in the presence of TK. All required co-factors and other related enzymes were assumed to be in excess following the hemolysate addition.) Solution of assay reagents was prepared as follows: 10 mg NADH per 100 ml TRIS buffer plus 0.5 ml GPH/TIM; 500 mg yeast R-5-P per 100 ml TRIS; and 0.05 M TRIS buffer at pH 7.6 with two to three drops of TRITON-X405.

Enzyme activity. In the present procedure, enzyme activity was expressed in terms of change in optical density per minute at 340 nm and 37 C. (Note: specific activity = enzyme activity per milligram of protein present.) The enzyme activity of the extract was determined by an indirect method, i.e., the difference between the TK activity attributed to hemolysate alone and that attributed to the hemolysate-extract mixture (Figure 2).

Protein determination. Protein content of each sample (hemolysate or extract) was determined by the method of Lowry, et al (27). Human serum albumin was used as the standard and the results were expressed as milligrams per milliliter of hemolysate or extract solution.

RESULTS AND DISCUSSION

Before we used the solvent denaturation as the initial step in the isolation of TK from human erythrocytes, we also attempted other methods in this laboratory. These methods included hydroxylapatite

$y/x = 2.8 \times 10^{-2}/0.4$
$= 7.0 (10^{-2})$ units per minute per ml enzyme extract

X-axis: Amount of extract added to 0.04 ml lysate

Y-axis: Change of optical density per minute at 340 nm and 37 C

Figure 2. Determination of the activity of transketolase derived from Hemolysate 1107A.

adsorption (25), ammonium sulfate fractionation (28), DEAE-cellulose adsorption (25,28), and acetone fractionation (28). None of these methods were completely satisfactory; the best was hydroxylapatite adsorption which gave a 14-fold purification and a yield of 47%. At one time we attempted to measure the activity of crudely isolated TK by simply estimating the GAP accumulated through the interaction between commercial preparations of Xu-5-P and R-5-P. However, the commercial yeast Xu-5-P was not in a sufficiently pure form (contaminated with TK) to warrant the attempt. Since commercially prepared Xu-5-P is rather expensive, the preparation of a pentose-5-phosphate equilibrium mixture in laboratory as a source of Xu-5-P was proposed but was not attempted because of the successful development of the present indirect method for measuring TK activity.

Table 1 shows the distribution of enzyme activity and protein content before and after the use of solvent denaturation. The data provided in this table represent the results obtained from five trials. Accordingly, the isolations were attempted on five different occasions with five hemolysates derived from blood donated by three individuals. As shown, the recovery of TK ranged from 57% to 64% with a mean of

5

Table 1. Summary of isolation of human erythrocyte transketolase (using solvent denaturation as the initial step) from blood of three donors

Isolation Step	Total Volume ml	Protein Content		Enzyme Activity			Enzyme Yield,%	Purification
		mg/ml	total	unit*/ml	total	sp. act.†		
Hemolysate 1107A	100	77.00	7700	55.05	5505	0.715	100	1
Enzyme extract	450	0.44	198	7.00	3150	15.909	57	22
Hemolysate 1107B	100	72.00	7200	57.60	5760	0.800	100	1
Enzyme extract	430	0.44	189	8.10	3479	18.409	60	23
Hemolysate 1107B	100	69.00	6900	64.15	6417	0.930	100	1
Enzyme extract	450	0.43	194	8.40	3790	19.535	59	21
Hemolysate 1107C	100	73.00	7300	59.50	5950	0.815	100	1
Enzyme extract	440	0.45	198	8.45	3718	18.778	63	23
Hemolysate 1107C	100	74.00	7400	60.00	5994	0.811	100	1
Enzyme extract	450	0.46	207	8.55	3848	18.587	64	23
Extract Mean ± S.D.							61 ± 3	21 ± 1

*1 unit = change of optical density (in arbitrary units) x 100 per minute at 340 nm and 37 C.
†specific activity (units per milligram).

61%. A range of 21- to 23-fold purification was achieved. Although these data do not contribute to sound statistical values primarily because of the small sample size, they tend to support the use of solvent denaturation as an effective initial step in the isolation of TK from human red cells. The 61% enzyme yield appears to be comparable with that obtained by Heinrich and Wiss (25) who, as mentioned before, used hydroxylapatite adsorption as the initial isolation step. Their recovery from using hydroxylapatite adsorption was 63% and their corresponding purification was 64-fold. However their recovery and purification values cannot be readily compared to the data presented in this table since the activity of their enzyme extract was measured without the addition of any hemolysate to the assay system. That is, the activity of their enzyme extract was determined by the estimation of the S-7-P accumulated in the assay system in the absence of potential interference by erythrocyte transaldolase and other hemolysate contaminants. It can be argued, therefore, that the higher yield of enzyme activity of their extract may not be due entirely to a specific adsorption capacity of hydroxylapatite. It is possible that the removal of transaldolase and other contaminants provided by the hemolysate can also account for such higher yield. For in the absence of transaldolase, both S-7-P and GAP may not be convertible to erythrose-4-phosphate (E-4-P) and fructose-6-phosphate (F-6-P) (Figure 1); this would result in the accumulation of more S-7-P or GAP.

The use of solvent denaturation as the initial step for TK isolation is relatively simple to perform and requires only about two hours to accomplish. Another seemingly important feature is that upon the completion of this process, over 90% of the hemoglobin has been removed. This may be an important contribution since it has been proposed that the determination of erythrocyte TK activity for the clinical evaluation of thiamin nutritional status should be estimated in the absence of hemoglobin if optical density measurement is involved. This argument is based upon the fact that a colored solution often contributes an unnecessarily high optical density background. If the hydroxylapatite adsorption method is used as the initial step for TK isolation, another procedure such as DEAE-cellulose adsorption will be required for the separation of the enzyme from the large amount of hemoglobin present(25). Preliminary findings indicate that the enzyme isolated by the use of solvent denaturation can be stored at 4 C for at least three days without losing any of its activity.

REFERENCES

1. SAUBERLICH, H.E. Biochemical alteration in thiamine deficiency –
   their interpretation. Am J Clin Nutr 20: 528–542, 1967

2. HORECKER, B.L., and P.Z. SMYRNIOTIS. The coenzyme function of
   thiamine pyrophosphate in pentose phosphate metabolism. J Am
   Chem Soc 75: 1009–1010, 1953

3. RACKER, E., G. DE LA HABA, and I.G. LEDER. Thiamine pyrophosphate,
   a coenzyme of transketolase. J Am Chem Soc 75: 1010–1011, 1953

4. BRIN, M. Erythrocyte as a biopsy tissue for functional evaluation
   of thiamine adequacy. JAMA 187: 762–766, 1964

5. BRIN, M., M.V. DIBBLE, A. PEEL, and E. MCMULLEN. Some preliminary
   findings on the nutritional status of the aged in Onondaga County,
   New York. Am J Clin Nutr 17: 240–258, 1965

6. THANANGKUL, O., and J.A. WHITAKER. Childhood thiamine deficiency
   in Northern Thailand. Am J Clin Nutr 18: 275–277, 1966

7. BRIN, M. Effects of thiamine deficiency and of oxythiamine on rat
   tissue transketolase. J Nutr 78: 179–183, 1962

8. HOFFMAN, I., A. KNAPP, K. RIETZ, and C. MILNER. Determination of
   transketolase activity in the blood. Clin Chim Acta 33: 415–421,
   1971

9. HORECKER, B.L., P.Z. SMYRNIOTIS, and H. KLENOW. The formation of
   sedoheptulose phosphate from pentose phosphate. J Biol Chem
   205: 661–682, 1953

10. VO-KHCATU, K.P., R.H. CLAYBURGH, and H.H. SANDSTEAD. An improved
    NADH-dependent transketolase assay for assessing thiamine nutriture.
    J Lab Clin Med 83: 983–989, 1974

11. HORECKER, B.L, P.Z. SMYRNIOTIS, and J. HURWITZ. The role of xy-
    lulose 5-phosphate in the transketolase reaction. J Biol Chem
    223: 1009–1019, 1953

12. BENEVENGA, N.J., W.J. STIELAW, and R.A. FREEDLAND. Factors af-
    fecting the activity of pentose phosphate-metabolizing enzymes in
    rat liver. J Nutr 84: 345–350, 1964

13. CHENG, C.H., and R.E. SHANK. A micro-fluorometric method for the
    determination of transketolase activity in rat liver. Fed Proc
    24: 690, 1964 (Abstract).

14. BRIN, M., M. TAI, A.S. OSTASHEVER, and H. KALINSKI. The effect of thiamine deficiency on the activity of erythrocyte hemolysate transketolase. J Nutr 71: 273-281, 1960

15. BRIN, M. Erythrocyte transketolase in early thiamine deficiency. Ann NY Acad Sci 98: 528-541, 1962

16. FENNELLY, J., O. FRANK, H. BAKER, and C.M. LEEVY. Transketolase activity in experimental thiamine deficiency and hepatic necrosis. Proc Soc Exp Biol Med 116: 875-877, 1964

17. BAKER, H., and O. FRANK. Vitamin analyses in medicine. Chapter 17. In: Modern Nutrition in Health and Disease (Fifth edition), edited by R.S. Goodhart and M.S. Shils. Philadelphia: Lea and Febiger, 1973. pp 531-546

18. BAKER, H. Discussion (of article by Sauberlich, reference 1 of this manuscript). Am J Clin Nutr 20: 543-546, 1967

19. BRIN, M. Transketolase. In: Methods of Enzymatic Analysis, edited by H.U. Bergmeyer. New York: Academic Press, Inc., 1974. pp 703-709

20. DE LA HABA, G., I.G. LEDER, and E. RACKER. Crystalline transketolase from Baker's yeast: isolation and properties. J Biol Chem 214: 409-426, 1955

21. DATTA, A.G., and E. RACKER. Mechanism of action of transketolase: I. Properties of crystalline yeast enzyme. J Biol Chem 236: 617-623, 1961

22. RACKER, E. Transketolase. In: The Enzymes (Volume V), edited by P.D. Boyer, H. Lardy, and K. Myrback. New York: Academic Press, Inc., 1961. pp 397-406

23. SIMPSON, F.J. Preparation and properties of transketolase from pork liver. Can J Biochem Physiol 38: 115-124, 1960

24. BONSIGNORE, A., S. PONTREMOLI, G. MANGIAROTTI, A. DE FLORA, and M. MANGIAROTTI. A direct interconversion: d-fructose 6-phosphate -sedoheptulose 7-phosphate and d-xylulose 5-phosphate catalyzed by the enzymes transketolase and transaldolase. J Biol Chem 237: 3597-3602, 1962

25. HEINRICH, P.C., and O. WISS. Transketolase from human erythrocytes: purification and properties. Helv Chim Acta 54: 2658-2668, 1971

26. OH, S.H., H.E. GANTHER, and W.G. HOEKSTRA. Selenium as a component of glutathione peroxidase isolated from ovine erythrocytes. Biochemistry 13: 1825-1829, 1974

27. LOWRY, O.H., N.J. ROSEBROUGH, A.L. FARR, and R.J. RANDALL. Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951

28. COOPER, T.G. Protein purification. Chapter 10. In: Tools of Biochemistry. New York: Wiley-Interscience, 1977. pp 355-404

Commander
US Army Medical Research and
Development Command
Fort Detrick, Frederick, MD 21701

Director
Walter Reed Army Institute of Research
Washington, DC 20012

Defense Documentation Center
ATTN: DDC-TCA   (12 cys)
Cameron Station
Alexandria, VA 22314

Commander
US Army Medical Research
Institute of Infectious Diseases
Fort Detrick, Frederick, MD 21701

Director of Defense Research and Engineering
ATTN: Asst Dir (Environmental and Life Sciences)
Washington, DC 20301

Commander
US Army Research Institute
of Environmental Medicine
Natick, MA 01760

The Surgeon General
ATTN: DASG-TLO
Washington, DC 20314

Commander
US Army Institute of Surgical Research
Brooke Army Medical Center
Fort Sam Houston, TX 78234

Superintendent
Academy of Health Sciences
US Army
ATTN: AHS-COM
Fort Sam Houston, TX 78234

Commander
US Army Institute of Dental Research
Washington, DC 20012

Assistant Dean
Inst & Rsch Support
Uniformed Services University
of Health Sciences
6917 Arlington Road
Bethesda, MD 20014

Commander
US Army Medical Bioengineering
Research & Development Laboratory
Fort Detrick, Frederick, MD 21701

Commander
US Army Environmental Hygiene Agency
Aberdeen Proving Ground, MD 21070

Commander
US Army Aeromedical Research Laboratory
Fort Rucker, AL 36362

US Army Research Office
ATTN: Chem & Bio Sci Div
P.O. Box 1221
Research Triangle Park, NC 27709

Director
US Army Biomedical Laboratory
Aberdeen Proving Ground
Edgewood Arsenal, MD 21010

Biological Sciences Division
Office of Naval Research
Arlington, VA 22217

Commander
Naval Medical Research Institute
National Naval Medical Center
Bethesda, MD 20014

Director of Life Sciences
USAF Office of Scientific Research (AFSC)
Bolling AFB
Washington, DC 20332

Commander
USAF School of Aerospace Medicine
Aerospace Medical Division
Brooks AFB, TX 78235

11

END

DATE
FILMED

9-80

DTIC